Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters

• Published in: Kidney international Vol. 92; no. 1; p. 26
• Main Authors: Ketteler, Markus, Block, Geoffrey A, Evenepoel, Pieter, Fukagawa, Masafumi, Herzog, Charles A, McCann, Linda, Moe, Sharon M, Shroff, Rukshana, Tonelli, Marcello A, Toussaint, Nigel D, Vervloet, Marc G, Leonard, Mary B
• Format: Journal Article
• Language: English
• Published: United States 01-07-2017
• Subjects: Biomarkers - blood; Bone Remodeling - drug effects; Calcium - blood; Chelating Agents - adverse effects; Chelating Agents - therapeutic use; Chronic Kidney Disease-Mineral and Bone Disorder - blood; Chronic Kidney Disease-Mineral and Bone Disorder - diagnosis; Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy; Consensus; Dietary Supplements - adverse effects; Evidence-Based Medicine - standards; Humans; Nephrology - standards; Parathyroid Hormone - blood; Phosphates - blood; Risk Factors; Treatment Outcome; Vitamin D - adverse effects; Vitamin D - therapeutic use; dialysis; bone mineral density; calcium; hyperphosphatemia; KDIGO CKD-MBD Guideline; kidney transplantation; hyperparathyroidism
• ISSN: 1523-1755
• DOI: 10.1016/j.kint.2017.04.006

The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD-mineral and bone disorder (MBD), treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD-MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.